385 related articles for article (PubMed ID: 36363516)
21. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
23. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
Wieland A; Frank DN; Harnke B; Bambha K
Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
[TBL] [Abstract][Full Text] [Related]
24. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
25. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
Mungamuri SK; Vijayasarathy K
Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
[TBL] [Abstract][Full Text] [Related]
26. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
27. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
Ezzaidi N; Zhang X; Coker OO; Yu J
Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
[TBL] [Abstract][Full Text] [Related]
28. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
29. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
30. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
[TBL] [Abstract][Full Text] [Related]
31. Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease.
Yu J; Zhang H; Chen L; Ruan Y; Chen Y; Liu Q
Front Cell Infect Microbiol; 2021; 11():698852. PubMed ID: 34568090
[TBL] [Abstract][Full Text] [Related]
32. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
Chu H; Williams B; Schnabl B
Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
[TBL] [Abstract][Full Text] [Related]
33. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial.
Craven L; Rahman A; Nair Parvathy S; Beaton M; Silverman J; Qumosani K; Hramiak I; Hegele R; Joy T; Meddings J; Urquhart B; Harvie R; McKenzie C; Summers K; Reid G; Burton JP; Silverman M
Am J Gastroenterol; 2020 Jul; 115(7):1055-1065. PubMed ID: 32618656
[TBL] [Abstract][Full Text] [Related]
34. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
Tokuhara D
Front Nutr; 2021; 8():700058. PubMed ID: 34250000
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
36. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
[TBL] [Abstract][Full Text] [Related]
37. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
38. Impacts of gut microbiota alteration on age-related chronic liver diseases.
Adhikary S; Esmeeta A; Dey A; Banerjee A; Saha B; Gopan P; Duttaroy AK; Pathak S
Dig Liver Dis; 2024 Jan; 56(1):112-122. PubMed ID: 37407321
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model.
Li H; Wang Q; Chen P; Zhou C; Zhang X; Chen L
Front Pharmacol; 2021; 12():788558. PubMed ID: 34938193
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
